Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03143374 · ClinicalTrials.gov registry record · Phase 2
PET Tau - Neurodegenerative Disease Imaging
A Phase 2 study of Neurodegenerative Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT03143374 is a Phase 2 study of Neurodegenerative Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 300 participants, below the 1,029-participant average among 5 other Neurodegenerative Disease trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03143374, a Phase 2 study of Neurodegenerative Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
Conditions Studied
Interventions
- DRUG 18F-AV-1451
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2016-08-23 |
| Est. Completion | 2030-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03143374
The ClinicalTrials.gov registry entry for NCT03143374 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,029-participant average among 5 other Neurodegenerative Disease trials with a reported enrollment target (71% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurodegenerative Disease appearing as the primary indexed condition, and to 1 intervention - of which 18F-AV-1451 is the first listed.
NCT03143374 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03143374 about?
NCT03143374 is a clinical study titled "PET Tau - Neurodegenerative Disease Imaging". The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such ...
What is the current status of trial NCT03143374?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2016-08-23. Estimated completion is 2030-09.
What conditions does trial NCT03143374 study?
This clinical trial studies the following conditions: Neurodegenerative Disease.
What interventions are being tested in trial NCT03143374?
The interventions under investigation include: 18F-AV-1451 (DRUG).
Who is sponsoring clinical trial NCT03143374?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03143374 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurodegenerative Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
RECRUITING
-
Mindfulness Walking Intervention to Enhance Resilience (iWalk)
RECRUITING · NA
-
Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population
COMPLETED
-
Cerebrospinal Fluid Repository
COMPLETED
-
Cause and Pathogenesis of Neurometabolic Disorders
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.